Abigail Hamilton
Psychiatric/Mental Health · Chicago, ILNPI 1790321693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 516 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 516 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- AbbVie$2K
- Johnson & Johnson$2K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$934
- Teva Pharmaceuticals USA, Inc.$774
- plus $4K from 21 others
What the payments were for
- Food & beverage$13,49399%
- Education$821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 99 | $2,660 |
| AbbVie | 110 | $2,323 |
| Johnson & Johnson | 46 | $1,570 |
| Alkermes, Inc. | 38 | $1,169 |
| Neurocrine Biosciences, Inc. | 34 | $934 |
| Teva Pharmaceuticals USA, Inc. | 23 | $774 |
| Axsome Therapeutics, Inc. | 23 | $693 |
| Vanda Pharmaceuticals Inc. | 24 | $630 |
| Otsuka America Pharmaceutical, Inc. | 25 | $584 |
| Supernus Pharmaceuticals, Inc. | 23 | $387 |
| Tris Pharma Inc | 10 | $352 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $326 |
| E.r. Squibb & Sons, L.L.C. | 6 | $241 |
| Lundbeck LLC | 11 | $212 |
| Revance Therapeutics, Inc. | 1 | $146 |
| Indivior Inc. | 6 | $118 |
| Braeburn Inc. | 4 | $89 |
| Corium, LLC | 4 | $85 |
| Merz North America, Inc. | 3 | $67 |
| Noven Therapeutics, LLC | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Atricure, Inc. | 1 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Viiv Healthcare Company | 1 | $26 |
| Neos Therapeutics, LP | 1 | $17 |
| Orexo US, Inc. | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$896
- CAPLYTA$844
- LYBALVI$479
- INGREZZA$409
- Auvelity$386
- VRAYLAR$375
- SPRAVATO$328
- INVEGA SUSTENNA$266
- Austedo XR$243
- ARISTADA INITIO$224
- DAXXIFY$146
- COBENFY$144
- UZEDY$127
- Fanapt$123
- ABILIFY MAINTENA$118
- ABILIFY ASIMTUFII$118
- Dyanavel XR$115
- QULIPTA$103
- UBRELVY$103
How this compares
$13,575 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbamazepine ErCarbamazepine | 16 | $766 |
| Quetiapine Fumarate | 20 | $341 |
| Fluvoxamine Maleate | 12 | $231 |
| Sertraline Hcl | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Chicago
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$151K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Julie CarbrayChicago$36K
- Anh NguyenChicago$9K
- Sherann IvyChicago$8K
- Annabella Vidal-RuizChicago$8K
- Dina Pierre-GrayChicago$7K
- Natalia RysmanowskaChicago$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.